Prophylactic antibiotics
PreclinicalSmall molecule
Prophylactic antibiotics is one of 14 small molecule programs targeting Acute Liver Failure. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Acute Liver Failure
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Medrol
PfizerPhase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Benadryl
PParkedale
Phase 2
Equine Anti-Thymocyte Globulin
NNational Cancer Institute (NCI)
Phase 2
Plasma Exchange
SanofiPreclinical
Granulocyte Colony-Stimulating Factor
SanofiPreclinical
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Preclinical
Exosome
PParacrine Therapeutics Dermatology Pte. Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bone1 trial
Platform Switched Implant and Bone Level Alteration
Unknown status·—·N/A·NCT02867982·36 enrolled
Antibiotics1 trial
Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06437964·226 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prophylactic antibiotics. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details